KRYSKrystal Biotech, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $389M
- 34% YoY
- Operating margin
- 41.5%
- 83% YoY
- EBITDA
- $167M
- 133% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -2.5×
- −$423M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear98% of net incomeCash flow under 80% of net income
- Dilutive SBCFired14% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $51M | $291M | $389M | 34% |
| Operating income | −$68M | −$145M | −$110M | $66M | $161M | 145% |
| Net income | −$70M | −$140M | $11M | $89M | $205M | 130% |
| Operating cash flow | −$48M | −$101M | −$89M | $123M | $201M | 63% |
| Capex | $68M | $53M | $12M | $4M | $12M | 182% |
| Stock-based comp | $15M | $33M | $40M | $49M | $55M | 11% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $18M · 26
- Net
- −$18M
Pay vs performance
No pay-versus-performance disclosure yet.